Business Description
NewAmsterdam Pharma Co NV
NAICS : 325412
SIC : 2834
ISIN : NL00150012L7
Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 835.43 | |||||
| Equity-to-Asset | 0.86 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 25.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -198.4 | |||||
| 3-Year EPS without NRI Growth Rate | -189.1 | |||||
| 3-Year FCF Growth Rate | -167.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 6.39 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.39 | |||||
| 9-Day RSI | 66 | |||||
| 14-Day RSI | 63.85 | |||||
| 6-1 Month Momentum % | 2.9 | |||||
| 12-1 Month Momentum % | 83.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.61 | |||||
| Quick Ratio | 10.61 | |||||
| Cash Ratio | 10.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | -6.87 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -532.98 | |||||
| Net Margin % | -592.12 | |||||
| FCF Margin % | -460.88 | |||||
| ROE % | -54.26 | |||||
| ROA % | -46.22 | |||||
| ROIC % | -562.05 | |||||
| ROC (Joel Greenblatt) % | -41291.1 | |||||
| ROCE % | -47.43 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 71.78 | |||||
| PB Ratio | 6.24 | |||||
| Price-to-Tangible-Book | 6.33 | |||||
| EV-to-EBIT | -12.76 | |||||
| EV-to-Forward-EBIT | -7.73 | |||||
| EV-to-EBITDA | -12.76 | |||||
| EV-to-Revenue | 68.69 | |||||
| EV-to-Forward-Revenue | 928.62 | |||||
| EV-to-FCF | -14.99 | |||||
| Price-to-Net-Current-Asset-Value | 6.33 | |||||
| Price-to-Net-Cash | 6.6 | |||||
| Earnings Yield (Greenblatt) % | -7.84 | |||||
| FCF Yield % | -5.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NAMS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NewAmsterdam Pharma Co NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 33.594 | ||
| EPS (TTM) ($) | -2.25 | ||
| Beta | 0 | ||
| Volatility % | 88.36 | ||
| 14-Day RSI | 63.85 | ||
| 14-Day ATR ($) | 1.57974 | ||
| 20-Day SMA ($) | 22.7805 | ||
| 12-1 Month Momentum % | 83.3 | ||
| 52-Week Range ($) | 10.502 - 27.29 | ||
| Shares Outstanding (Mil) | 107.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NewAmsterdam Pharma Co NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NewAmsterdam Pharma Co NV Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NewAmsterdam Pharma Co NV Frequently Asked Questions
What is NewAmsterdam Pharma Co NV(NAMS)'s stock price today?
The current price of NAMS is $25.95. The 52 week high of NAMS is $27.29 and 52 week low is $10.50.
When is next earnings date of NewAmsterdam Pharma Co NV(NAMS)?
The next earnings date of NewAmsterdam Pharma Co NV(NAMS) is 2025-02-28 Est..
Does NewAmsterdam Pharma Co NV(NAMS) pay dividends? If so, how much?
NewAmsterdam Pharma Co NV(NAMS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers